Oncology drugs is one of the fastest-growing segments in the global pharmaceutical industry. Over the next five years, oncology drug sales are expected to exceed USD 90 billion—a staggering number
The newest of Novartis’s cancer drugs, Kisqali, has received European Union approval. Kisqali will be used as a first-line treatment for a difficult-to-treat breast cancer. The company expects Kisqali to be a
With cancer rates on the rise, oncology drugs are more valuable and necessary now than ever before. For pharmaceutical companies, oncology drugs are guaranteed to generate revenue—and for patients, oncology